drugset / Trial / NCT00485966
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, open-label, multicenter, efficacy, safety, and pharmacodynamic study of CX-3543 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2007-06
- Primary completion
- —
- Completion
- 2008-06
Outcome
Outcome not reported
Stopped (Enrollment): “This study was withdrawn prior to patient enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quarfloxacin | Unknown | 360 mg/m2 | — |